| pubmed-article:18507749 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0020971 | lld:lifeskim |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0032961 | lld:lifeskim |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0021289 | lld:lifeskim |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0015965 | lld:lifeskim |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0312853 | lld:lifeskim |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:18507749 | lifeskim:mentions | umls-concept:C0140430 | lld:lifeskim |
| pubmed-article:18507749 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:18507749 | pubmed:dateCreated | 2008-8-20 | lld:pubmed |
| pubmed-article:18507749 | pubmed:abstractText | The objective was the evaluation of the effect of the Dutch national routine antenatal RhIG (anti-D) immunization prevention (RAADP) program comprising one single dose of 200 microg (1000 IU) of RhIG in the 30th week of pregnancy, restricted to women without a living child. | lld:pubmed |
| pubmed-article:18507749 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18507749 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18507749 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18507749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18507749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18507749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18507749 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18507749 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18507749 | pubmed:issn | 0041-1132 | lld:pubmed |
| pubmed-article:18507749 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:18507749 | pubmed:author | pubmed-author:BonselGouke... | lld:pubmed |
| pubmed-article:18507749 | pubmed:author | pubmed-author:de HaasMasjaM | lld:pubmed |
| pubmed-article:18507749 | pubmed:author | pubmed-author:VrijkotteTanj... | lld:pubmed |
| pubmed-article:18507749 | pubmed:author | pubmed-author:KoelewijnJoke... | lld:pubmed |
| pubmed-article:18507749 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18507749 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:18507749 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18507749 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18507749 | pubmed:pagination | 1721-9 | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:meshHeading | pubmed-meshheading:18507749... | lld:pubmed |
| pubmed-article:18507749 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18507749 | pubmed:articleTitle | One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. | lld:pubmed |
| pubmed-article:18507749 | pubmed:affiliation | Sanquin Research, Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:18507749 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18507749 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18507749 | lld:pubmed |
